Linagliptin
Links shared publicly online about this topic
No Proven Added Benefit Of Linagliptin
medicalnewstoday.com — “Drug manufacturer deviates from appropriate comparator therapy specified by the G-BA Linagliptin (trade name: Trajenta®) has been approved since August 2011 to improve blood” View full resource at medicalnewstoday.com
Most Recently Shared on January 10, 2012 at 8:05 am By:
No Proven Added Benefit Of Linagliptin http://t.co/gt5RfskF #diabetes
Tradjenta (linagliptin) Tablets For Diabetes Type 2 Approved By FDA
medicalnewstoday.com — “The FDA has approved Tradjenta (linagliptin) tablets to control blood sugar in adults with diabetes type two - to be used along with diet and exercise, Boehringer Ingelheim Pharmaceuticals, Inc. a” View full resource at medicalnewstoday.com
Most Recently Shared on May 4, 2011 at 1:08 am By:
Tradjenta (linagliptin) Tablets For Diabetes Type 2 Approved By FDA: The FDA has approved Tradjenta (linagliptin... http://bit.ly/kwMtjw
Tradjenta (linagliptin) Tablets For Diabetes Type 2 Approved By FDA
medicalnewstoday.com — “The FDA has approved Tradjenta (linagliptin) tablets to control blood sugar in adults with diabetes type two - to be used along with diet and exercise, Boehringer Ingelheim Pharmaceuticals, Inc. a” View full resource at medicalnewstoday.com
Most Recently Shared on May 3, 2011 at 9:05 pm By:
MNT Drug Approvals Health News
Tradjenta (linagliptin) Tablets For Diabetes Type 2 Approved By FDA http://mnt.to/3Vmq #regulatory
FDA Approves Linagliptin Tablets For The Treatment Of Type 2 Diabetes
medicalnewstoday.com — “Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along w” View full resource at medicalnewstoday.com
Most Recently Shared on May 3, 2011 at 12:05 pm By:
MNT Drug Approvals Health News
FDA Approves Linagliptin Tablets For The Treatment Of Type 2 Diabetes http://mnt.to/3VjP #regulatory
FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes : FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
dlife.com — “FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes : FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes” View full resource at dlife.com
Most Recently Shared on May 4, 2011 at 1:57 am By:
FDA Approves Tradjentaâ„¢ (linagliptin) Tablets for the Treatment of Type 2 Diabetes: read more (Source: Diabete... http://bit.ly/mg0OL5
Phase 3 study of linagliptin for the treatment of type 2 diabetes - ONA
oncologynurseadvisor.com — “Boehringer Ingelheim announced results from its Phase 3 studies of linagliptin for the treatment of type 2 diabetes.” View full resource at oncologynurseadvisor.com
Most Recently Shared on September 23, 2010 at 4:19 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of linagliptin for the treatment of type 2 diabetes http://goo.gl/fb/QbLXm
FDA Approves Tradjenta(TM) (linagliptin) for Treatment of Type 2 Diabetes
disabled-world.com — “U.S. Food and Drug Administration has approved Tradjenta (linagliptin) tablets a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes” View full resource at disabled-world.com
Most Recently Shared on May 3, 2011 at 7:03 pm By:
Disabled World Health Advocate and Health News
FDA Approves Tradjenta(TM) (linagliptin) for Treatment of Type 2 Diabetes http://ff.im/-Cz1bO
EMA CHMP recommends approval of linagliptin for type 2 diabetes
news-medical.net — “Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.” View full resource at news-medical.net
Most Recently Shared on June 24, 2011 at 8:47 pm By:
EMA CHMP recommends approval of linagliptin for type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company ... http://bit.ly/kjFU5X
Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD
news-medical.net — “New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.” View full resource at news-medical.net
Most Recently Shared on September 22, 2010 at 1:40 pm By:
Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD: New Phase III data found that investigati... http://bit.ly/b9wXJj
Linagliptin Helps Renally Impaired Diabetics - Renal and Urology News
renalandurologynews.com — “SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, appears to be a good treatment option for patients with type 2 diabetes and severe renal impairment, researchers announced at the 71st Scientific Sessions of the American Diabetes Association.” View full resource at renalandurologynews.com
Most Recently Shared on July 6, 2011 at 12:09 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Linagliptin Helps Renally Impaired Diabetics: SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, a... http://bit.ly/ncoPQL
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe | Business Wire
businesswire.com — “Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today received a positive opinion from the European Medicines Agency’s (EMA) medicinal” View full resource at businesswire.com
Most Recently Shared on June 24, 2011 at 2:45 pm By:
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe: INGELHEIM, Germany--(BUSINES... http://bit.ly/jqrcRT
Linagliptin Helps Renally Impaired Diabetics - Renal and Urology News
renalandurologynews.com — “SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, appears to be a good treatment option for patients with type 2 diabetes and severe renal impairment, researchers announced at the 71st Scientific Sessions of the American Diabetes Association.” View full resource at renalandurologynews.com
Most Recently Shared on June 30, 2011 at 3:37 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Linagliptin Helps Renally Impaired Diabetics: SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, a... http://bit.ly/mBhXSU
FDA Approves Linagliptin for Type 2 Diabetes : Hospitalist News
ehospitalistnews.com — “Hospitalist News Digital Network is the online destination and multimedia properties of Hospitalist News, the independent news publication. Our breaking news covers all areas of hospital-based practice including cardiovascular disease; critical care medicine; diabetes, endocrinology and metabolism; gastroenterology; infectious diseases; hematology; imaging; nephrology; neurology; palliative care and hospice; perioperative medicine; pulmonary disease; pediatrics; practice trends; and trauma. We a” View full resource at ehospitalistnews.com
Most Recently Shared on May 2, 2011 at 9:54 pm By:
Damian McNamara Health Communicator
RT @HspNews: FDA Approves Linagliptin for Type 2 Diabetes http://bit.ly/joNvsU
Phase III Trials Show Linagliptin Effectively Reduces Blood Glucose, With Good Tolerability
medicalnewstoday.com — “Orlando, 26 June 2010: Linagliptin, a dipeptidyl dipeptidase (DPP)-4 inhibitor being developed by Boehringer Ingelheim, achieves significant reductions in blood glucose in patients with type 2 dia” View full resource at medicalnewstoday.com
Most Recently Shared on June 28, 2010 at 5:19 pm By:
Phase III Trials Show Linagliptin Effectively Reduces Blood Glucose, With Good Tolerability http://mnt.to/3FsP #healthnews
New Phase III Data Further Support The Safety And Efficacy Profile Of Boehringer Ingelheim's Investigational Drug Linagliptin
medicalnewstoday.com — “New data from the linagliptin late stage clinical trial programme were presented this week at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). The studies incl” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2010 at 1:49 pm By:
Urology & Nephrology OW Health
New Phase III Data Further Support The Safety And Efficacy Profile Of Boehringer Ingelheim's Investigational Drug ... http://mnt.to/f/3KbM
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Diabetes News
The latest diabetes news published daily. Articles from research centers, universities and prestigious journals.
-
Diabetes, Type 2
Organizing type 2 diabetes resources shared by health experts, advocates, and organizations into WisdomCards.
-
MNT Drug Approvals
The latest regulatory affairs / drug approvals news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
